(AOF) – Integragen announced an unaudited turnover of 11.75 million euros in 2023, down 7% compared to 2022. This company specializing in the decryption of the human genome explains this drop in revenue ” mainly by the drop in activities linked to Covid-19″, “partially offset by a significant increase in revenue linked to other sectors of activity”. The company’s cash position as of December 31, 2023 amounts to €2.9 million, in line with the company’s expectations and the 2023 budget
While the SeqOIA platform experienced growth of 9%, activities related to microbiology with the P2M platform of the Pasteur Institute, closely linked to the Covid-19 pandemic, decreased by 37%.
As the 5-year contract with GCS SeqOIA ends on February 29, 2024, IntegraGen has implemented a right-sizing effort to support improved profitability, resulting in a “significant” reduction in its total workforce beginning in February 2024.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
